# A Study of MEDI-575 in Patients With Advanced Solid Malignancies

> **NCT01102400** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 22 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** MEDI-575

## Key facts

- **NCT ID:** NCT01102400
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01102400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01102400, "A Study of MEDI-575 in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01102400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*